http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b40638dd63f6752655b6a40062882bf9
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Hoff D. Von Hoff Von Hoff |
| name | Daniel D Von Hoff Daniel D. Von Hoff |
| given-name | Daniel D. Von Daniel D. Daniel Daniel D |
| organization-name | Authors' Affiliations: 1Clinical Translational Research Division; 2Cancer and Cell Biology Division; 3Genetic Basis of Human Disease Division, The Translational Genomics Research Institute, Phoenix; and 4Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, Arizona Translational Genomics Research Institute (TGen), Phoenix, AZ, USA From the Departments of Pharmacology/Toxicology and Medicine, Division of Hematology/Oncology, Arizona Cancer Center/University of Arizona Health Sciences Center, Tucson; Translational Genomics Research Institute, Phoenix, AZ; and American BioScience, Inc, Santa Monica, CA. Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ, USA; Molecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA From the Translational Genomics Research Institute (TGen); Caris Life Sciences Phoenix; TGen Clinical Research Service at Scottsdale Healthcare; Mayo Clinic Arizona, Scottsdale; University of Arizona Cancer Center, Tucson, AZ; Cancer Centers of the Carolinas, Greenville, SC; Tower Cancer Research Foundation, Beverly Hills, CA; Central Indiana Cancer Centers, Indianapolis, IN; Texas Oncology at Tyler, Tyler, TX; and AAIPharma, Wilmington, NC. The Translational Genomics Research Institute, Phoenix, Arizona 3Clinical Translational Research, and From the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX; South Texas Oncology and Hematology, PA, San Antonio, TX; Department of Medicine, Division of Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX; School of Pharmacy, University of Connecticut, Farmington, CT; and Sugen, Inc, Redwood City, CA. 3Translational Genomics Research Institute (TGen), Phoenix, Arizona. From the Divisions of Urology and Oncology, University of Texas Health Science Center, San Antonio, Texas HonorHealth Research Institute, Scottsdale, Arizona; Translational Genomics Research Institute, an Affiliate of City of Hope, Phoenix, Arizona Molecular Medicine Division, Translational Genomics Research Institute (TGen), Scottsdale, Arizona, USA; Oncology, HonorHealth Clinical Research Institute, Phoenix, Arizona, USA Authors' Affiliations: 1Genomic Health, Inc., Redwood City, California; and 2Clinical Translational Research Division, Translational Genomics Research Institute, Scottsdale, Arizona Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare/TGen Scottsdale AZ Authors' Affiliations: 1Karmanos Cancer Institute, Detroit, Michigan; 2Johns Hopkins University, Baltimore, Maryland; 3Genentech, Inc., South San Francisco, California; and 4Translational Genomics Research Institute (TGen) and Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, Arizona Institute for Drug Development, Cancer Therapy and Research Center Authors' Affiliations: 1Cylene Pharmaceuticals, San Diego, California; and 2Translational Genomics Research Institute, Phoenix, Arizona Department of Medicine, Division of Oncology University of Texas, Health Science Centre at San Antonio San Antonio Texas; Cancer Therapy and Research Center of South Texas San Antonio Texas University of Texas Health Science Center at San Antonio, Medicine/Oncology, San Antonio, TX, USA Authors' Affiliations: Departments 1Radiation Oncology, 2Experimental Diagnostic Imaging, 3Imaging Physics, and 4Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas; 5Head and Neck Surgery; and 6TGEN, Phoenix, Arizona From the Institute for Drug Development, Cancer Therapy and Research Center; and The University of Texas Health Science Center, San Antonio, TX. 1Arizona Cancer Center, 1Translational Genomics Research Institute, Phoenix, Arizona.; 2HonorHealth, Scottsdale, Arizona. Division of Medical Oncology University of Texas Health Science Center at San Antonio San Antonio Texas Translational Genomics Research Institute (TGEN), Phoenix, Arizona, USA 4Translational Genomics Research Institute, Phoenix, Arizona; Departments of Author's Affiliation: Division of Clinical Translational Research, Translational Genomics Research Institute, Phoenix, Arizona Authors' Affiliations: 1Mayo Clinic;; 2Virginia G. Piper Cancer Center;; 3The Translational Genomics Research Institute (TGen), Scottsdale, Arizona; and Departments of Medicine University of Texas Health Science Center San Antonio Texas Translational Genomics Research Institute and HonorHealth – Oncology, 445 North Fifth St, Suite 600, Phoenix, AZ 85004, USA 4Translational Genomics Research Institute, Phoenix, Arizona 1HonorHealth, Scottsdale, Arizona and TGen, Phoenix, Arizona. The University of Texas Health Science Center at San Antonio, Texas, The Department of Medicine/Division of Onocology, San Antonio, Texas, USA 8Translational Genomics Research Institute, Phoenix, Arizona The Department of Medicine, Division of Oncology, University of Texas Health Science Center at San Antonio and Cancer Therapy and Research Center of South Texas, San Antonio, Texas, USA 3Translational Genomics Research Institute, Phoenix, Arizona; and 4Virginia G. Piper Cancer Center Clinical Trials, HonorHealth Research Institute, Scottsdale, Arizona.; 5Translational Genomics Research Institute (TGen), Clinical Translational Research Division, Phoenix, Arizona. Virginia G. Piper Cancer Center, HonorHealth, Phoenix, Arizona; Translational Genomic Research Institute, Phoenix, Arizona From the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio; The University of Texas Health Science Center at San Antonio, San Antonio; Division of Oncology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX; and Schering-Plough Research Institute, Kenilworth, NJ. Authors' Affiliations: 1University of Colorado Cancer Center, Aurora, Colorado; 2Translational Genomics Research Institute (TGen); 3Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, Arizona; 4Roswell Park Cancer Institute, Buffalo, New York; 5Ardea Biosciences, Inc., San Diego, California; and 6Bayer HealthCare Pharmaceuticals, Montville, New Jersey; Authors' Affiliations: 1University of Colorado Cancer Center, Aurora, Colorado; 2Translational Genomics Research Institute (TGen); 3Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, Arizona; 4Roswell Park Cancer Institute, Buffalo, New York; 5Ardea Biosciences, Inc., San Diego, California; and 6Bayer HealthCare Pharmaceuticals, Montville, New Jersey From the Institute for Drug Development, Cancer Therapy and Research Center; The University of Texas Health Science Center at San Antonio; and Brooke Army Medical Center, San Antonio; Joe Arrington Cancer Center, Lubbock, TX; and Daiichi Pharmaceutical Corporation, Montvale, NJ. From the Institute for Drug Development, Cancer Therapy and Research Center, and The University of Texas Health Science Center at San Antonio, San Antonio; Brooke Army Medical Center, Fort Sam Houston, TX; and Hoffmann-LaRoche, Inc, Nutley, NJ. From the Institute for Drug Development, Cancer Therapy and Research Center, and The University of Texas Health Science Center at San Antonio, San Antonio, TX; and Otsuka America Pharmaceutical, Inc, Palo Alto, CA. 1Cancer Therapy and Research Center, 3University of Arizona Cancer Center, Tucson, Arizona University of Texas Health Science Center and Cancer Therapy and Research Center, San Antonio, Texas 78284 7Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, Arizona. Gene Expression Laboratory, The Salk Institute for Biological Studies, San Diego, California 92138 From the Institute for Drug Development, Cancer Therapy and Research Center; and the University of Texas Health Science Center, San Antonio, TX. 3Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, Arizona; 5Virginia G. Piper Cancer Center Honor Health, Scottsdale, Arizona. Authors' Affiliations: 1CanBas Co., Ltd., Numazu, Japan; 2Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; and 3Translational Genomics Research Institute (TGen), Phoenix, Arizona Daniel D. Von Hoff, Ramesh K. Ramanathan, TGen/Virginia G. Piper Cancer Center; Mitesh J. Borad, Mayo Clinic; Ronald L. Korn, Scottsdale Medical Imaging, Scottsdale, AZ; Daniel A. Laheru, N.V. Rajeshkumar, and Anirban Maitra, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD; Lon S. Smith, South Texas Oncology/Hematology, San Antonio, TX; Tina E. Wood, University of Alabama at Birmingham, Birmingham, AL; Neil Desai, Vuong Trieu, Jose L. Iglesias, Hui Zhang, and... From the Institute for Drug DevelopmentCancer Therapy and Research Center; University of Texas Health Science Center; and Brooke Army Medical Center, San Antonio, TX; and Pharmaceuticals Division, Bayer Corporation, West Haven, CT. From the Institute for Drug Development, Cancer Therapy and Research Center, and the University of Texas Health Science Center at San Antonio, San Antonio, TX; U.S. Oncology, and Baylor University Medical Center, Dallas, TX; and Pfizer Pharmaceuticals, Inc, Groton, CT. Authors' Affiliations: 1Virginia G. Piper Cancer Center at Scottsdale Healthcare (VGPCC)/TGen, Scottsdale; 2Mayo Clinic, Phoenix, Arizona; 3Norton Healthcare, Louisville, Kentucky; 4US Oncology Research - Florida Institute of Research, Cancer Center, Ocoee, Florida; 5US Oncology Research - Rocky Mountain Cancer Centers, Denver, Colorado; 6Premiere Oncology, Santa Monica; and 7Nektar Therapeutics, San Francisco, California 1Translational Genomic Research Institute and Virginia G. Piper Cancer Center, Scottsdale, Arizona. Authors' Affiliation: Clinical Translational Research Division, Translational Genomics Research Institute, Scottsdale, Arizona 1 Computational Biology Division, Translational Genomics Research Institute, Phoenix, AZ 85004, 2Theoretical Division and Center for Nonlinear Studies, Los Alamos National Laboratory, Los Alamos, NM 87545, 3Department of Computational Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, 4Department of Biology, University of New Mexico, Albuquerque, NM 87131, 5Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ 85004 and 6Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ 86011, USA Molecular Medicine Division, Translational Genomics Research Institute, Phoenix, Arizona, USA 3Clinical Translational Research Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona. Authors' Affiliations: 1Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; and 2Translational Genomics Research Institute, Phoenix, Arizona Department of Medicine, Division of Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA 5The Translational Genomics Research Institute (TGen), Phoenix, Arizona. 3TGen, Phoenix, Arizona Authors' Affiliations: 1Genentech Inc., South San Francisco, California; 2Translational Genomics Research Institute (TGen) and TGen Clinical Research Institute, Scottsdale, Arizona; 3Johns Hopkins University, Baltimore, Maryland; and the 4Karmanos Cancer Institute, Detroit, Michigan From the Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland Authors' Affiliations: 1Clinical Translational Research Division and 2Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona From the Institute for Drug DevelopmentCancer Therapy and Research Center and the University of Texas Health Science Center, San Antonio, TX; and Pro-Neuron, Inc, Gaithersburg, MD. 1Translational Genomics Research Institute, Phoenix, Arizona and 3TGen, Phoenix, Arizona; and 1Division of Clinical Translational Research, Translational Genomics Research Institute, Phoenix, Arizona and From the University of Texas Health Science Center at San Antonio, San Antonio, TX; Pharmacia & Upjohn Company, Kalamazoo, MI; Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX; and Brooke Army Medical Center, Ft. Sam Houston, TX Translational Genomics Research Institute, Phoenix, Arizona 85004, United States From the Institute for Drug Development, Cancer Therapy and Research Center, and Department of Medicine, Division of Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, and MGI Pharma, Inc, Bloomington, MN. 4Translational Genomic Research Institute and Virginia G. Piper Cancer Center, Phoenix, Arizona. 1Arizona Cancer Center and Departments of Authors' Affiliations: 1School of Life Sciences, Arizona State University, Tempe; 2Translational Genomics Institute, Phoenix; and 3Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona Authors' Affiliations: 1Clinical Translational Research Division, 2Tissue Microarray Core Services, and 3Genetic Basis of Human Disease Division, Translational Genomics Research Institute, Phoenix, Arizona; and 4Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, USA; The Translational Genomics Research Institute, Phoenix, USA From the Institute for Drug Development, Cancer Therapy and Research Center, and University of Texas Health Science Center at San Antonio, San Antonio, TX; Dana-Farber Partners in Cancer Care, Boston, MA; Cancer Institute of New Jersey, New Brunswick; Knoll Pharmaceutical Company, Mount Olive, NJ. Department of Oncology, Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, Arizona, USA Institute for Drug Development, Cancer Therapy & Research Center, 14960 Omicron Drive, San Antonio, Texas 78245-3217 The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA;; The Cancer Therapy and Research Center, San Antonio, Texas, USA; 1Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona. Department of Medicine, Division of Oncology The University of Texas Health Science Center at San Antonio, San Antonio, Texas Institute for Drug Development, San Antonio, USA 2TGen, Phoenix, Arizona Translational Genomic Research Institute and Virginia G Piper Cancer Center, Phoenix, United States of America From the Department of RadiologyBeth Israel Deaconess Medical Center, Boston, MA; The Arizona Cancer Center, University of Arizona Health Sciences Center, and Cancer Technologies, Inc, Tucson, AZ; and University of Texas Health Science Center at San Antonio and Cancer Therapy and Research Center, San Antonio, TX. Translational Genomics Research Institute (TGen) 3Translational Genomics Research Institute, Phoenix, Arizona |
Incoming Links
Total number of triples: 487.